Further understanding of the clinical impact of the DDX41 mutations, including learning further prognostic or clinical information of DDX41 mutant AML/MDS patients, and studying whether DDX41 mutations can be targetable for therapeutic or preventive applications would be essential. The gene discussed is DDX41; the disease is acute myeloid leukemia.